{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:59:49Z","timestamp":1793825989591,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-53629-z","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T14:03:36Z","timestamp":1729778616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Ashley E.","family":"Culver-Cochran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-3564","authenticated-orcid":false,"given":"Aishlin","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hueneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangmin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4817-1258","authenticated-orcid":false,"given":"Averil","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"VanCauwenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Perentesis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5771-7462","authenticated-orcid":false,"given":"Daniel T.","family":"Starczynowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"53629_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3324\/haematol.2021.280161","volume":"107","author":"JM Rowe","year":"2022","unstructured":"Rowe, J. M. The \u201c7+3\u201d regimen in acute myeloid leukemia. Haematologica 107, 3 (2022).","journal-title":"Haematologica"},{"key":"53629_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol, F., Schlenk, R. F., Heuser, M. & Ganser, A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 126, 319\u2013327 (2015).","journal-title":"Blood"},{"key":"53629_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"53629_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2018.187575","volume":"103","author":"F Thol","year":"2018","unstructured":"Thol, F. Can we forecast induction failure in acute myeloid leukemia? Haematologica 103, 375\u2013377 (2018).","journal-title":"Haematologica"},{"key":"53629_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett, A., Wetzler, M. & Lowenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29, 487\u2013494 (2011).","journal-title":"J. Clin. Oncol."},{"key":"53629_CR6","doi-asserted-by":"publisher","first-page":"896426","DOI":"10.3389\/fonc.2022.896426","volume":"12","author":"J Niu","year":"2022","unstructured":"Niu, J., Peng, D. & Liu, L. Drug resistance mechanisms of acute myeloid leukemia stem cells. Front. Oncol. 12, 896426 (2022).","journal-title":"Front. Oncol."},{"key":"53629_CR7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/s41375-019-0402-3","volume":"33","author":"NA McNeer","year":"2019","unstructured":"McNeer, N. A. et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia 33, 1934\u20131943 (2019).","journal-title":"Leukemia"},{"key":"53629_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nm.4255","volume":"23","author":"C Schneider","year":"2017","unstructured":"Schneider, C. et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat. Med. 23, 250\u2013255 (2017).","journal-title":"Nat. Med."},{"key":"53629_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/MOH.0b013e3283257b42","volume":"16","author":"K Mrozek","year":"2009","unstructured":"Mrozek, K., Radmacher, M. D., Bloomfield, C. D. & Marcucci, G. Molecular signatures in acute myeloid leukemia. Curr. Opin. Hematol. 16, 64\u201369 (2009).","journal-title":"Curr. Opin. Hematol."},{"key":"53629_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"53629_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/leu.2011.48","volume":"25","author":"K Theilgaard-Monch","year":"2011","unstructured":"Theilgaard-Monch, K. et al. Gene expression profiling in MDS and AML: potential and future avenues. Leukemia 25, 909\u2013920 (2011).","journal-title":"Leukemia"},{"key":"53629_CR12","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJMoa040465","volume":"350","author":"PJ Valk","year":"2004","unstructured":"Valk, P. J. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617\u20131628 (2004).","journal-title":"N. Engl. J. Med."},{"key":"53629_CR13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/bloodadvances.2020003727","volume":"5","author":"CJ Walker","year":"2021","unstructured":"Walker, C. J. et al. Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Blood Adv. 5, 1474\u20131482 (2021).","journal-title":"Blood Adv."},{"key":"53629_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2008-04-153239","volume":"113","author":"BJ Wouters","year":"2009","unstructured":"Wouters, B. J., Lowenberg, B. & Delwel, R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 113, 291\u2013298 (2009).","journal-title":"Blood"},{"key":"53629_CR15","doi-asserted-by":"crossref","unstructured":"Di Francesco, B., et al. NF-kappaB: a druggable target in acute myeloid leukemia. Cancers 14, 3557 (2022).","DOI":"10.3390\/cancers14143557"},{"key":"53629_CR16","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.18632\/oncotarget.3545","volume":"6","author":"J Zhou","year":"2015","unstructured":"Zhou, J., Ching, Y. Q. & Chng, W. J. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target. Oncotarget 6, 5490\u20135500 (2015).","journal-title":"Oncotarget"},{"key":"53629_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3835(01)00795-9","volume":"181","author":"T Gilmore","year":"2002","unstructured":"Gilmore, T., Gapuzan, M. E., Kalaitzidis, D. & Starczynowski, D. Rel\/NF-kappa B\/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Lett. 181, 1\u20139 (2002).","journal-title":"Cancer Lett."},{"key":"53629_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi, K. & Karin, M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat. Rev. Immunol. 18, 309\u2013324 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"53629_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fonc.2013.00120","volume":"3","author":"P Godwin","year":"2013","unstructured":"Godwin, P. et al. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front. Oncol. 3, 120 (2013).","journal-title":"Front. Oncol."},{"key":"53629_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.exphem.2013.02.002","volume":"41","author":"MC Bosman","year":"2013","unstructured":"Bosman, M. C., Schuringa, J. J., Quax, W. J. & Vellenga, E. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-kappaB and the accumulation of MCL-1. Exp. Hematol. 41, 530\u2013538 e531 (2013).","journal-title":"Exp. Hematol."},{"key":"53629_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/leu.2008.297","volume":"23","author":"I Paz-Priel","year":"2009","unstructured":"Paz-Priel, I., Ghosal, A. K., Kowalski, J. & Friedman, A. D. C\/EBPalpha or C\/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters. Leukemia 23, 365\u2013374 (2009).","journal-title":"Leukemia"},{"key":"53629_CR22","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","volume":"11","author":"C Duy","year":"2021","unstructured":"Duy, C. et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. 11, 1542\u20131561 (2021).","journal-title":"Cancer Discov."},{"key":"53629_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nature07969","volume":"459","author":"M Kato","year":"2009","unstructured":"Kato, M. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712\u2013716 (2009).","journal-title":"Nature"},{"key":"53629_CR24","doi-asserted-by":"crossref","unstructured":"Zhao, D. et al. TP53 mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell transplantation. Cancers 15, 3210 (2023).","DOI":"10.3390\/cancers15123210"},{"key":"53629_CR25","doi-asserted-by":"crossref","unstructured":"Crowley, L. C., Marfell, B. J., Scott, A. P. & Waterhouse, N. J. Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry. Cold Spring Harb. Protoc. 2016, pdb-prot087288 (2016).","DOI":"10.1101\/pdb.prot087288"},{"key":"53629_CR26","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston, D. R. & Davis, M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin. Cancer Res. 23, 3489\u20133498 (2017).","journal-title":"Clin. Cancer Res."},{"key":"53629_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.536442","volume":"11","author":"MA Smith","year":"2020","unstructured":"Smith, M. A. et al. TNFAIP3 plays a role in aging of the hematopoietic system. Front. Immunol. 11, 536442 (2020).","journal-title":"Front. Immunol."},{"key":"53629_CR28","doi-asserted-by":"publisher","first-page":"103914","DOI":"10.1016\/j.cellimm.2019.04.002","volume":"340","author":"BA Malynn","year":"2019","unstructured":"Malynn, B. A. & Ma, A. A20: A multifunctional tool for regulating immunity and preventing disease. Cell Immunol. 340, 103914 (2019).","journal-title":"Cell Immunol."},{"key":"53629_CR29","doi-asserted-by":"crossref","unstructured":"Martens, A. & van Loo, G. A20 at the crossroads of cell death, inflammation, and autoimmunity. Cold Spring Harb. Perspect. Biol. 12, a036418 (2020).","DOI":"10.1101\/cshperspect.a036418"},{"key":"53629_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41590-020-0634-4","volume":"21","author":"B Razani","year":"2020","unstructured":"Razani, B. et al. Non-catalytic ubiquitin binding by A20 prevents psoriatic arthritis-like disease and inflammation. Nat. Immunol. 21, 422\u2013433 (2020).","journal-title":"Nat. Immunol."},{"key":"53629_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrm.2016.149","volume":"18","author":"R Weinlich","year":"2017","unstructured":"Weinlich, R., Oberst, A., Beere, H. M. & Green, D. R. Necroptosis in development, inflammation and disease. Nat. Rev. Mol. Cell Biol. 18, 127\u2013136 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"53629_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41573-023-00749-8","volume":"22","author":"K Hadian","year":"2023","unstructured":"Hadian, K. & Stockwell, B. R. The therapeutic potential of targeting regulated non-apoptotic cell death. Nat. Rev. Drug Discov. 22, 723\u2013742 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"53629_CR33","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/cdd.2017.65","volume":"24","author":"S Grootjans","year":"2017","unstructured":"Grootjans, S., Vanden Berghe, T. & Vandenabeele, P. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ. 24, 1184\u20131195 (2017).","journal-title":"Cell Death Differ."},{"key":"53629_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/cr.2015.56","volume":"25","author":"GB Koo","year":"2015","unstructured":"Koo, G. B. et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 25, 707\u2013725 (2015).","journal-title":"Cell Res."},{"key":"53629_CR35","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281.e1224 (2019).","journal-title":"Cell"},{"key":"53629_CR36","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","volume":"98","author":"ML Guzman","year":"2001","unstructured":"Guzman, M. L. et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301\u20132307 (2001).","journal-title":"Blood"},{"key":"53629_CR37","doi-asserted-by":"crossref","unstructured":"Ramadass, V., Vaiyapuri, T. & Tergaonkar, V. Small molecule NF-kappaB pathway inhibitors in clinic. Int. J. Mol. Sci. 21, 5164 (2020).","DOI":"10.3390\/ijms21145164"},{"key":"53629_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi1782","volume":"10","author":"S Zhu","year":"2024","unstructured":"Zhu, S. et al. RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells. Sci. Adv. 10, eadi1782 (2024).","journal-title":"Sci. Adv."},{"key":"53629_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584974","volume":"10","author":"Y Wei","year":"2020","unstructured":"Wei, Y. et al. Targeting Bcl-2 proteins in acute myeloid leukemia. Front Oncol. 10, 584974 (2020).","journal-title":"Front Oncol."},{"key":"53629_CR40","doi-asserted-by":"publisher","first-page":"339ra370","DOI":"10.1126\/scitranslmed.aad2986","volume":"8","author":"S McComb","year":"2016","unstructured":"McComb, S. et al. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Sci. Transl. Med. 8, 339ra370 (2016).","journal-title":"Sci. Transl. Med."},{"key":"53629_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fcell.2019.00040","volume":"7","author":"C Mezzatesta","year":"2019","unstructured":"Mezzatesta, C. & Bornhauser, B. C. Exploiting necroptosis for therapy of acute lymphoblastic leukemia. Front Cell Dev. Biol. 7, 40 (2019).","journal-title":"Front Cell Dev. Biol."},{"key":"53629_CR42","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/ni.3172","volume":"16","author":"M Onizawa","year":"2015","unstructured":"Onizawa, M. et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat. Immunol. 16, 618\u2013627 (2015).","journal-title":"Nat. Immunol."},{"key":"53629_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49038-8","volume":"9","author":"MM Nakagawa","year":"2019","unstructured":"Nakagawa, M. M. & Rathinam, C. V. A20 deficiency in hematopoietic stem cells causes lymphopenia and myeloproliferation due to elevated Interferon-gamma signals. Sci. Rep. 9, 12658 (2019).","journal-title":"Sci. Rep."},{"key":"53629_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.scr.2018.10.020","volume":"33","author":"MM Nakagawa","year":"2018","unstructured":"Nakagawa, M. M., Davis, H. & Rathinam, C. V. A20 deficiency in multipotent progenitors perturbs quiescence of hematopoietic stem cells. Stem Cell Res. 33, 199\u2013205 (2018).","journal-title":"Stem Cell Res."},{"key":"53629_CR45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41590-020-0663-z","volume":"21","author":"T Muto","year":"2020","unstructured":"Muto, T. et al. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nat. Immunol. 21, 535\u2013545 (2020).","journal-title":"Nat. Immunol."},{"key":"53629_CR46","doi-asserted-by":"crossref","unstructured":"Jakobsen, N. A. et al. Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. Cell Stem Cell 31, 1127\u20131144.e17 (2024).","DOI":"10.1016\/j.stem.2024.05.010"},{"key":"53629_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-022-08960-4","volume":"23","author":"I Jakobsen","year":"2022","unstructured":"Jakobsen, I., Sundkvist, M., Bjorn, N., Green, H. & Lotfi, K. Early changes in gene expression profiles in AML patients during induction chemotherapy. BMC Genomics 23, 752 (2022).","journal-title":"BMC Genomics"},{"key":"53629_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05691-6","volume":"14","author":"K Ye","year":"2023","unstructured":"Ye, K., Chen, Z. & Xu, Y. The double-edged functions of necroptosis. Cell Death Dis. 14, 163 (2023).","journal-title":"Cell Death Dis."},{"key":"53629_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood-2018-05-847335","volume":"133","author":"PN Wagner","year":"2019","unstructured":"Wagner, P. N. et al. Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice. Blood 133, 107\u2013120 (2019).","journal-title":"Blood"},{"key":"53629_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1182\/blood-2018-11-886242","volume":"133","author":"BA Croker","year":"2019","unstructured":"Croker, B. A. & Kelliher, M. A. BID-ding on necroptosis in MDS. Blood 133, 103\u2013104 (2019).","journal-title":"Blood"},{"key":"53629_CR51","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.apsb.2020.01.007","volume":"10","author":"Y Wu","year":"2020","unstructured":"Wu, Y., Dong, G. & Sheng, C. Targeting necroptosis in anticancer therapy: mechanisms and modulators. Acta Pharm. Sin. B 10, 1601\u20131618 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"53629_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7695","volume":"14","author":"L Barreyro","year":"2022","unstructured":"Barreyro, L. et al. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Sci. Transl. Med. 14, eabb7695 (2022).","journal-title":"Sci. Transl. Med."},{"key":"53629_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-019-5548-x","volume":"20","author":"K Choi","year":"2019","unstructured":"Choi, K. & Ratner, N. iGEAK: an interactive gene expression analysis kit for seamless workflow using the R\/shiny platform. BMC Genomics 20, 177 (2019).","journal-title":"BMC Genomics"},{"key":"53629_CR54","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"53629_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 128 (2013).","journal-title":"BMC Bioinform."},{"key":"53629_CR56","doi-asserted-by":"publisher","first-page":"D1138","DOI":"10.1093\/nar\/gkad993","volume":"52","author":"MH Gislason","year":"2024","unstructured":"Gislason, M. H. et al. BloodSpot 3.0: a database of gene and protein expression data in normal and malignant haematopoiesis. Nucleic Acids Res. 52, D1138\u2013D1142 (2024).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53629-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53629-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:04:48Z","timestamp":1729782288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53629-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53629"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53629-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DTS serves on the scientific advisory board at Kurome Therapeutics and is a consultant for and\/or received funding from Kurome Therapeutics, Captor Therapeutics, Treeline Biosciences, and Tolero Therapeutics. DTS has equity in Kurome Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9189"}}